Optimal Management of Diabetic Kidney Disease
- Author:
Jae-Han JEON
1
Author Information
- Publication Type:Opinion
- From:Journal of Korean Diabetes 2025;26(1):1-4
- CountryRepublic of Korea
- Language:Korean
- Abstract: Diabetic kidney disease (DKD) is a leading cause of chronic kidney disease (CKD) and end-stage renal disease in Korea, with an increasing prevalence due to the aging population and rising diabetes cases. While glycemic control has improved, DKD prevention requires a multifaceted approach addressing blood pressure, lipid levels, and lifestyle factors. This study reviews the current status of DKD management in Korea and proposes strategies for optimization. Patients with DKD frequently present with comorbidities such as hypertension, dyslipidemia, and obesity. Although renin-angiotensin-aldosterone system inhibitors are commonly prescribed, the utilization of newer therapies, such as sodium glucose cotransporter 2 (SGLT2) inhibitors, remains low. Effective management necessitates comprehensive risk factor control, careful medication selection, and public education on the risk of nephrotoxic drugs and unverified supplements. Policy changes are needed to improve access to advanced therapies and personalized care. Expanding the use of SGLT2 inhibitors, glucagon-like peptide-1 receptor agonists, and mineralocorticoid receptor antagonists can delay disease progression and enhance patient outcomes. Additionally, public education and monitoring systems are critical to prevent the misuse of nephrotoxic agents. In conclusion, DKD is a growing public health challenge in Korea. Collaborative efforts among healthcare providers, policymakers, and patients are needed to improve patient care through integrated, data-driven strategies.
